Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

• Main Authors: Moreno C., Berg T., Tanwandee T., Thongsawat S., Van Vlierberghe H., Zeuzem S., Lenz O., Peeters M., Sekar V., De Smedt G.
• 格式: 雜誌
• 出版: 2017
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84861188748&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/42832
• 機構: Chiang Mai University

Background & Aims: TMC435 is an investigational, once-daily, oral NS3/4A protease inhibitor currently in phase III development for the treatment of hepatitis C virus (HCV) infection. Phase I and II studies in patients infected with HCV genotype 1 have demonstrated that TMC435 is generally well...